Skip to main content

Table 1 Characteristics of studies included in the present meta-analysis

From: Clinical significance of FBXW7 tumor suppressor gene mutations and expression in human colorectal cancer: a systemic review and meta-analysis

Detection of FBXW7 mutation/expression Study Study Region Recruitment time No. of patients Clinical Stage FBXW7 status method Cut off Antibody source Dilution Case: Low/High (MT/WT)a Median follow-up months Analysis method OS HR(95%CI) DFS HR(95%CI) Quality score
Mutation Chang, 2015 [11] Taiwan 2000-2009 1519 TNM I-IV MassArray NA NA NA 114/1405 NA Univariate 1.00 (0.98–1.02) NA 8
Mouradov, 2013 [19] Australia 2002-2004 822 TNM II-III Sanger sequencing NA NA NA 41/781 32.2 Univariate 0.96 (0.45–2.06) NA 7
Korphaisarn, 2017 [16] USA 2009-2015 527 TNM IV NGS NA NA NA 43/484 30.4 Multivariate 2.00 (1.27–3.16) NA 8
Iwatsuki, 2010 [14] Japan 1993-1999 93 Duke A-D qRT-PCR Median NA NA 46/47 36 Multivariate 1.98 (1.26–3.27) NA 7
Gao, 2019 [12] China 2015-2016 207 TNM I-IV MiSeq NA NA NA 33/174 23 Univariate 0.59 (0.21–1.68) 0.75 (0.32–1.79) 7
Expression He, 2019 [13] China 2009-2011 140 TNM I-IV IHC NA Abcam, USA 1:500 84/56 NA Univariate 2.30 (0.92–5.76) 2.45 (1.22–4.92) 6
Liu, 2018 [18] China 2010-2015 509 TNM I-IV IHC Score 4 Abcam, USA 1:200 359/150 NA Univariate 2.22 (1.40–3.45) NA 6
Li, 2018 [17] China 2007-2009 276 TNM I-IV IHC Score 1 Bethyl, USA NA 60/216 NA Multivariate 3.57 (2.23–5.71) 4.63 (2.65–8.13) 7
Tang, 2016 [24] China 2011-2011 50 Duke A-D IHC score 3 Santa Cruz, USA 1:60 23/27 NA Univariate 1.04 (0.12–9.42) NA 7
Kawashita, 2017 [15] Japan 2001-2009 56 NA IHC Score 3 Abcam, USA 1:100 24/32 55 Univariate 1.98 (0.42–9.26) 1.50 (0.79–2.85) 7
  1. a Low/High indicates low expression of FBXW7 versus high expression of FBXW7 in studies investigating the RNA or protein level of FBXW7, and the MT/WT implies the mutation of FBXW7 versus wild type of FBXW7 in studies investigating the mutation rate of FBXW7